137 related articles for article (PubMed ID: 1312076)
1. A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies.
Coia L; Krigel R; Hanks G; Comis R; Algazy K; Peters R; McCulloch W; Schien P
Int J Radiat Oncol Biol Phys; 1992; 22(4):791-4. PubMed ID: 1312076
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of total body irradiation in chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphomas.
Roncadin M; Arcicasa M; Bortolus R; Trovó MG; Carbone A; Tirelli U; De Paoli A; Franchin G; Grigoletto E
Cancer Invest; 1991; 9(4):403-7. PubMed ID: 1884246
[TBL] [Abstract][Full Text] [Related]
3. Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution.
Roncadin M; Arcicasa M; Zagonel V; Bortolus R; Valeri P; Pinto A; De Paoli A; Franchin G; Carbone A; Trovò MG
Cancer; 1994 Aug; 74(3):978-84. PubMed ID: 8039128
[TBL] [Abstract][Full Text] [Related]
4. Dose-escalated total body irradiation and autologous stem cell transplantation for refractory hematologic malignancy.
McAfee SL; Powell SN; Colby C; Spitzer TR
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):151-6. PubMed ID: 12007954
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I/II trial.
Demirer T; Petersen FB; Appelbaum FR; Barnett TA; Sanders J; Deeg HJ; Storb R; Doney K; Bensinger WI; Shannon-Dorcy K
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1103-9. PubMed ID: 7607931
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma.
Song DY; Jones RJ; Welsh JS; Haulk TL; Korman LT; Noga S; Goodman S; Herman M; Mann R; Marcellus D; Vogelsang G; Ambinder RF; Abrams RA
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):166-71. PubMed ID: 12909229
[TBL] [Abstract][Full Text] [Related]
7. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Eilender DS; Hulburd K; Rodriguez DH; Pemberton PA; Pluda JM; Dan MD; Pettit GR; Chen BD; Al-Katib AM
J Clin Oncol; 1998 Jan; 16(1):56-62. PubMed ID: 9440723
[TBL] [Abstract][Full Text] [Related]
10. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP
J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698
[TBL] [Abstract][Full Text] [Related]
11. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations.
Robins HI; Longo WL; Steeves RA; Cohen JD; Schmitt CL; Neville AJ; O'Keefe S; Lagoni R; Riggs C
Int J Radiat Oncol Biol Phys; 1990 Apr; 18(4):909-20. PubMed ID: 2182581
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
14. Milestones in the development of Lym-1 therapy.
DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction.
McDonald S; Meyerowitz C; Smudzin T; Rubin P
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):747-54. PubMed ID: 8040020
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Van Den Neste E; Louviaux I; Michaux JL; Delannoy A; Michaux L; Sonet A; Bosly A; Doyen C; Mineur P; André M; Straetmans N; Coche E; Venet C; Duprez T; Ferrant A
Leukemia; 2000 Jun; 14(6):1136-42. PubMed ID: 10865980
[TBL] [Abstract][Full Text] [Related]
18. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
20. WR-2721 as cytotoxic and radioprotective agent in treatment of murine lymphoma with total body irradiation.
Coia LR; Brown DQ; Hardiman J
NCI Monogr; 1988; (6):235-9. PubMed ID: 2832762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
